US National Children's Hospital
New York Presbyterian University Hospital of Columbia and Cornell
New Treatment For Uroepithelial Carcinoma Receives Fda Fast Track Designation With Encouraging Initial Results
New Drug For IDH1 Mutation/Relapsed/Refractory Acute Myeloid Leukaemia With Good Complete Remission Rates And Manageable Toxicity
Genetic Modification Of Immune Cells To Make Them Tireless, Cold-Blooded "Cancer Cell Killers"!
Heidelberg University Hospital
